Press Room

News / Jun 22, 2017

Hovione receives B Corp Certification

Hovione became a Certified B Corp at the B Corp Summer Summit 2017, in Cascais, Portugal

B Corporation Certification logo | Hovione

Hovione is the first Chemical/Pharmaceutical Company integrating this innovative community of companies that use the power of business to solve social and environmental problems.

As a Certified B Corporation Hovione wants to contribute to redefine success in business, meeting the highest standards of social and environmental performance, setting its team members for success and personal satisfaction and aspiring to use the power of markets to solve social and environmental problems. Hovione believe that B Corps, and especially those that are family businesses, through the power of their collective voice, are competing to be Best for the World® and through them society will enjoy a more shared and durable prosperity.

To certify as a B Corp, a set of rigorous social and environmental standards must be met. This is achieved through the B Impact Assessment process that requires four principle areas to be assessed: governance model, workers, environment protection and community involvement, including the impact on its suppliers. Hovione's certification process began almost a year ago. During this period B Lab assessed Hovione's policies and procedures in all locations with its operations around the world (Portugal, Ireland, United States and Asia). They concluded that Hovione follows all the appropriate models and can thus be part of this movement.

This is a global movement of people using business as a force for goodTM with a vision that one day all companies compete not only to be the best in the world, but the Best for the World®.

 

Hovione receives B Corp Certification | Hovione
Sofia Burnay, Carolina Serras Pereira, Marcello Palazzi and Diane Villax

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025